Tigecycline: First of a New Class of Antimicrobial Agents

  title={Tigecycline: First of a New Class of Antimicrobial Agents},
  author={Warren E. Rose and Michael Joseph Rybak},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  • W. RoseM. Rybak
  • Published 1 August 2006
  • Biology, Medicine
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Tigecycline is the first commercially available member of the glycylcyclines, a new class of antimicrobial agents. The glycylcyclines are derivatives of the tetracycline antibiotics, with structural modifications that allow for potent gram‐positive, gram‐negative, and anaerobic activity, including certain multidrug‐resistant strains. The enhanced activity can be attributed to stronger binding affinity and enhanced protection against several mechanisms of resistance that affect other antibiotic… 

Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review

Tigecycline showed in vitro susceptibility to Coxiella spp, Rickettsia spp.

Review of Tigecycline: Focus on Clinical Utilization

The antimicrobial profile and available clinical data for the first member of the glycylcycline class, tigecycline, may provide a therapeutic option in select patients, given its broad spectrum of activity, including multi-drug resistant (MDR) strains.

Role of Combination Antimicrobial Therapy for Vancomycin‐Resistant Enterococcus faecium Infections: Review of the Current Evidence

The mechanisms of action and resistance to currently available anti‐VRE antimicrobial agents including newer agents such as oritavancin and dalbavancins will be presented and novel combination therapies including β‐lactams and fosfomycin, and the promising results from in vitro, animal studies, and clinical experience in the treatment of VRE faecium will be discussed.

In vitro activity of tigecycline as a therapeutic option against multidrug-resistant Acinetobacter spp.

Tigecycline has been shown to have potent in vitro activity against MDR Acinetobacter spp.

Combination therapy for carbapenem-resistant Gram-negative bacteria

Clinical evidence of the major drugs utilized in combination schemes and how they should be prescribed considering pharmacokinetic/pharmacodynamic characteristics against CR GNB will be reviewed in this article.

Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates

It is demonstrated that this collection of strains is largely resistant to monotherapies of carbapenems, fluoroquinolones, folate pathway antagonists, cephalosporins, and most tetracyclines.

In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated strains

Tigecycline showed good activity against MRSA strains in vitro, and this discrepancy warrants further investigations into the preferred test conditions for tigecYcline.

Non-antimicrobial strategies for the prevention and treatment of infections by multidrug-resistant gram-negative bacilli

In vivo, AOA-2 in combination with colistin reduced bacterial spleen and lung loads, bacteremia and mortality rates, in comparison with the monotherapy with colistsin, and in vivo, the therapeutic efficacy of Aoa-2 against A. baumannii and P. aeruginosa in experimental murine models of peritoneal sepsis and pneumonia was evaluated.



In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides.

This study compared the in vitro activity of tigecycline with that of tetracycline, vancomycin and teicoplanin against 157 unrelated, non-duplicate clinical isolates obtained in the microbiology laboratory during 1998–2001.

In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-Intermediate Staphylococcus aureus and Other Resistant Gram-Positive Pathogens

The data suggest that tigecycline and daptomycin may offer therapeutic options against clinically relevant resistant pathogens for which current alternatives for treatment are limited.

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.

  • A. GalesR. Jones
  • Biology, Medicine
    Diagnostic microbiology and infectious disease
  • 2000

In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.

The excellent expanded broad-spectrum activity of tigecycline demonstrated in vitro against clinical isolates confirmed its potential utility for pathogens associated with complicated skin and skin-structure infections or complicated intra-abdominal infections.

In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.